Navigation Links
Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO

.com.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. Genta is partnered with IDIS (http://www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

    -- the Company's ability to obtain necessary regulatory approval for

       Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

       European Medicines Agency ("EMEA");

    -- the safety and efficacy of the Company's products or product

       candidates;

    -- the Company's assessment of its clinical trials;

    -- the commencement and completion of clinical trials;

    -- the Company's ability to develop, manufacture, license and sell its

     
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 /PRNewswire/ ... Summary GlobalData,s new report, "Germany ... market data on the Germany Gynecological Devices market. ... dollars, volume (in units) and average prices (in ... Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization ...
(Date:9/17/2014)... , Sept. 17, 2014  Dr. Stephen Loyd ... White House today for National Recovery Month, stars in ... advocates released today. Consumer advocates were also joined by ... spoke out after losing her fiancée because of a ... doctor had a history of crack cocaine abuse. Proposition ...
(Date:9/17/2014)... Mass. , Sept. 17, 2014 /PRNewswire/ ... disease/ulcerative colitis (CD/UC) patients eligible for biologic ... receive a biologic. Surveyed gastroenterologists cite patients, ... reason for low penetration rates, followed by ... and UC patients receiving biologics, Janssen Biotech,s ...
Breaking Medicine Technology:Germany Gynecological Devices Market Outlook to 2020 2Germany Gynecological Devices Market Outlook to 2020 3Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3
(Date:9/18/2014)... Dr. Suzaunna Clark, Psychologist, Life Coach ... beauty has to be seen to be believed and ... order to be used. Together, both lead to hearts ... how to do both. , Dr. Clark ... Healing Hearts system, which provides professional guidance on dealing ...
(Date:9/18/2014)... The Nautilus/ASG relationship is perfectly suited ... and even long term data archiving, to verticals that ... time. This includes media and entertainment, life sciences and ... Nautilus and ASG-Digital Archive will drive down the cost ... is pleased to work with ASG to expand its ...
(Date:9/17/2014)... Recently, UWDress.com, an innovative company that ... occasion outfits, has released its 2014 empire waist ... has launched a big sale for these new and ... deeply discounted rates, from 15 to 65 percent off. ... on using comfortable to wear materials. Its elegant items ...
(Date:9/17/2014)... Charlotte, NC (PRWEB) September 18, 2014 ... , U.S. emergency departments treat an estimated 173,285 sports- ... and adolescents every year. Soon, a blood test may ... concussion is and how long recovery will take. ... reported that they have found a way to ...
(Date:9/17/2014)... CA (PRWEB) September 17, 2014 ... & Drug Administration report titled “Adverse Events Associated ... as a Dermal Filler,” unapproved use of Expression, ... has resulted in adverse reactions including discoloration, lumps, ... products with FDA approval for cosmetic use include ...
Breaking Medicine News(10 mins):Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 3Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 3Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 3Health News:Simon Ourian, Kim Kardashian's Cosmetic Surgeon, Warns About Illegal Use of Expression as a Dermal Filler 2
... New research from the University of New Hampshire shows that ... are more likely to move on to harder illicit drugs as ... pot will use other illicit drugs as young adults has more ... according to the new research. In fact, the strongest predictor of ...
... Wyss Institute for Biologically Inspired Engineering at Harvard and ... in one of the most microscopic forms of lifebacteria. ... Nature . In studying the development of ... populations most adept at withstanding doses of antibiotics are ...
... 1, 2010 Very low birthweight and very preterm infants are ... hospitals with neonatal intensive care units specially equipped to care ... at those specialized facilities. "We encourage women who have ... about the care their baby may need after birth and ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... treat high blood sugar in type 2 diabetics may hold ... to extremely preliminary findings in a mouse study. In ... report that metformin was associated with a substantial reduction (up ...
... needed to address breast cancer in Mexican-origin women in ... of Texas MD Anderson Cancer Center, which was published ... Among the Mexican-origin women with breast cancer who were ... than the national average for non-Hispanic white women. This ...
... University of Illinois scientists will learn whether protein supplements ... cardiovascular disease and retain physical function, thanks to a ... (NIH). "Patients with kidney failure face many health ... common forms of heart disease, and they also develop ...
Cached Medicine News:Health News:Risk of marijuana's 'gateway effect' overblown, new UNH research shows 2Health News:New research finds evidence of charitable behavior in bacteria 2Health News:Neonatal intensive care units critical to infant survival 2Health News:Diabetes Drug Metformin Linked to Lower Lung Cancer Rate in Mice 2Health News:Diabetes Drug Metformin Linked to Lower Lung Cancer Rate in Mice 3Health News:Targeted strategies needed to find, prevent and treat breast cancer among Mexican-origin women 2Health News:Targeted strategies needed to find, prevent and treat breast cancer among Mexican-origin women 3Health News:Will extra protein and exercise help dialysis patients? U of I profs get $2.1 million to find out 2Health News:Will extra protein and exercise help dialysis patients? U of I profs get $2.1 million to find out 3
Coude Foley Catheters (Latex) 2-Way Amber...
Silicone Elastomer-Coated Latex Foley Catheters 3-Way...
Silicone Foley Catheters 3-Way...
Midstream Catch Kits...
Medicine Products: